An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.

Anthony W. Tolcher,Pamela N. Munster,Lee S. Rosen,Curran Murphy,Christian Argueta,Keisuke Kuida,Rodrigo Ruiz-Soto,Filip Janku

An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.

2019

Anthony W. Tolcher
Pamela N. Munster
Lee S. Rosen
Curran Murphy
Christian Argueta
Keisuke Kuida
Rodrigo Ruiz-Soto
Filip Janku

TPS2666Background: Rebastinib is a potent, orally administered, kinase switch control inhibitor selectively targeting the tunica interna endothelial cell kinase (TIE2). TIE2 is primarily expressed ...

Keywords:

Rebastinib
Oncology
Pathology
Carboplatin
Tolerability
Medicine
Internal medicine
Pharmacokinetics
Kinase
in patient
Endothelial stem cell
open label
Tunica

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations